Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Centogene stock logo
CNTG
Centogene
$0.17
$0.25
$1.53
$8.80M-0.67150,868 shs8.36 million shs
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$19.66
-0.9%
$18.00
$15.45
$35.84
$572.83M1.1421,895 shs284,050 shs
DermTech, Inc. stock logo
DMTK
DermTech
$0.19
$0.09
$3.90
$3.29M2.481.07 million shs3.66 million shs
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$19.27
-1.4%
$20.20
$14.57
$25.11
$595.17M1.03287,442 shs203,031 shs
Personalis, Inc. stock logo
PSNL
Personalis
$6.37
-7.9%
$5.65
$1.61
$7.79
$611.21M1.951.16 million shs1.23 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Centogene stock logo
CNTG
Centogene
0.00%0.00%0.00%0.00%-68.61%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-0.91%-3.08%+6.62%-0.20%+12.47%
DermTech, Inc. stock logo
DMTK
DermTech
0.00%0.00%0.00%0.00%+6.45%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-1.43%-3.94%-11.28%+1.42%-1.68%
Personalis, Inc. stock logo
PSNL
Personalis
-7.95%-15.68%+8.70%+94.21%+310.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Centogene stock logo
CNTG
Centogene
N/AN/AN/AN/AN/AN/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
2.3411 of 5 stars
3.52.00.00.02.62.50.0
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/AN/AN/AN/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
3.5862 of 5 stars
2.31.00.04.12.93.30.6
Personalis, Inc. stock logo
PSNL
Personalis
3.4869 of 5 stars
2.51.00.04.22.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Centogene stock logo
CNTG
Centogene
0.00
N/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
3.00
Buy$37.0088.20% Upside
DermTech, Inc. stock logo
DMTK
DermTech
0.00
N/AN/AN/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
2.50
Moderate Buy$24.0024.55% Upside
Personalis, Inc. stock logo
PSNL
Personalis
3.00
Buy$7.6720.36% Upside

Current Analyst Ratings Breakdown

Latest FLGT, PSNL, CNTG, CSTL, and DMTK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.00
5/15/2025
Personalis, Inc. stock logo
PSNL
Personalis
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
5/7/2025
Personalis, Inc. stock logo
PSNL
Personalis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$8.00 ➝ $9.00
5/6/2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $35.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$42.00 ➝ $37.00
5/5/2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Centogene stock logo
CNTG
Centogene
$48.54M0.00N/AN/A($1.01) per share0.00
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$332.07M1.71$0.98 per share20.16$16.28 per share1.21
DermTech, Inc. stock logo
DMTK
DermTech
$15.66M0.00N/AN/A$1.67 per share0.00
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$283.47M2.07N/AN/A$36.92 per share0.52
Personalis, Inc. stock logo
PSNL
Personalis
$84.61M6.65N/AN/A$2.87 per share2.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Centogene stock logo
CNTG
Centogene
-$38.58MN/A0.00N/AN/AN/AN/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$18.25M-$0.19N/AN/AN/A-1.46%3.41%2.95%8/4/2025 (Estimated)
DermTech, Inc. stock logo
DMTK
DermTech
-$100.89M-$2.70N/AN/AN/A-572.19%-138.79%-68.96%N/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$42.71M-$1.33N/AN/AN/A-13.94%-2.19%-2.02%8/1/2025 (Estimated)
Personalis, Inc. stock logo
PSNL
Personalis
-$81.28M-$1.29N/AN/AN/A-98.10%-48.78%-34.70%8/6/2025 (Estimated)

Latest FLGT, PSNL, CNTG, CSTL, and DMTK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Personalis, Inc. stock logo
PSNL
Personalis
-$0.25N/AN/AN/A$20.12 millionN/A
8/4/2025Q2 2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.44N/AN/AN/A$71.53 millionN/A
8/1/2025Q2 2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$0.23N/AN/AN/A$76.21 millionN/A
5/6/2025Q1 2025
Personalis, Inc. stock logo
PSNL
Personalis
-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million
5/5/2025Q1 2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million
5/2/2025Q1 2025
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Centogene stock logo
CNTG
Centogene
N/AN/AN/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
N/AN/AN/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Centogene stock logo
CNTG
Centogene
N/A
1.02
0.96
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
0.02
9.37
9.19
DermTech, Inc. stock logo
DMTK
DermTech
N/A
3.53
3.46
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/A
6.32
6.32
Personalis, Inc. stock logo
PSNL
Personalis
N/A
6.91
6.74

Institutional Ownership

CompanyInstitutional Ownership
Centogene stock logo
CNTG
Centogene
9.94%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
92.60%
DermTech, Inc. stock logo
DMTK
DermTech
20.45%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
48.06%
Personalis, Inc. stock logo
PSNL
Personalis
61.91%

Insider Ownership

CompanyInsider Ownership
Centogene stock logo
CNTG
Centogene
1.93%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
6.50%
DermTech, Inc. stock logo
DMTK
DermTech
5.10%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
31.76%
Personalis, Inc. stock logo
PSNL
Personalis
3.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Centogene stock logo
CNTG
Centogene
81027.08 millionN/ANot Optionable
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
54028.87 million27.00 millionOptionable
DermTech, Inc. stock logo
DMTK
DermTech
26034.96 million33.18 millionOptionable
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
1,31330.44 million20.78 millionOptionable
Personalis, Inc. stock logo
PSNL
Personalis
40088.32 million84.97 millionOptionable

Recent News About These Companies

Personalis, Inc. (PSNL) - Yahoo Finance
Personalis (NASDAQ:PSNL) Shares Down 6.1% - Time to Sell?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Centogene stock logo

Centogene NASDAQ:CNTG

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.

Castle Biosciences stock logo

Castle Biosciences NASDAQ:CSTL

$19.66 -0.18 (-0.91%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$19.66 +0.00 (+0.03%)
As of 07/11/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

DermTech stock logo

DermTech NASDAQ:DMTK

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

Fulgent Genetics stock logo

Fulgent Genetics NASDAQ:FLGT

$19.27 -0.28 (-1.43%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$19.28 +0.02 (+0.08%)
As of 07/11/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Personalis stock logo

Personalis NASDAQ:PSNL

$6.37 -0.55 (-7.95%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$6.53 +0.16 (+2.53%)
As of 07/11/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.